Minerva Neurosciences | NERV - Ebitda


Minerva Neurosciences reported $-4.36M in EBITDA for its fiscal quarter ending in September of 2024.





Ebitda Change Date
Acadia Pharmaceuticals USD -1.62M 21.94M Mar/2026
Adma Biologics USD 61.07M 12.52M Mar/2026
ALKERMES USD 139.22M 58.96M Jun/2026
Alterity Therapeutics Limited AUD -7.72M 2.99M Jun/2023
AstraZeneca USD 5.16B 510M Jun/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Cipla INR 14.03B 4.48B Jun/2026
Clal Biotechnology ILS -5.3M 2.09M Dec/2022
Compugen USD -9.02M 1.12M Mar/2026
CSL USD 3.13B 1.17B Dec/2025
Eli Lilly USD 10.29B 1.86B Mar/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Grifols EUR 482.04M 7.04M Sep/2025
Halozyme Therapeutics USD 328.81M 109.24M Jun/2026
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
J&J USD 8.27B 1.08B Mar/2026
Merck USD -1.54B 7.84B Mar/2026
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 6.01B 18M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sanofi EUR 3.69B 375M Jun/2026
Takeda JPY 364.46B 214.21B Jun/2026
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024